EarlyONCO
First-in-human and Phase I/II oncology clinical trials
Heads:
Pr. Gérard Zalcman, Dr. Jacques Médioni, Pr. Pierre Laurent-Puig
Objectives
Accelerate the early clinical development of innovative oncology therapies by providing start-ups, biotechs, medtechs and biopharmaceutical companies with end-to-end support, from clinical strategy to early-phase trial implementation, through coordinated access to AP-HP expertise, infrastructure and patient populations.
Operator (s)
Technology and expertise
An integrated AP-HP platform dedicated to early clinical development in oncology, bringing together clinical, scientific, technological and regulatory expertise.
EarlyONCO provides a single point of entry to AP-HP expertise and infrastructure, from early clinical strategy and regulatory support to trial implementation, from patient identification and recruitment to translational research platforms.
Services and activities
Scientific & Regulatory Support Hub
Robust clinical development strategy & roadmap
Study feasibility assessment
Protocol design & optimization
Regulatory pathway guidance
Biomarker strategy development
Medical expert panels & therapeutic expertise
Patient & Translational Hub
Connecting patients, data and precision oncology
AI-assisted patient pre-screening and trial matching
Access to the AP-HP Clinical Data Warehouse
Molecular tumor boards supporting patient screening and precision medicine
Translational research infrastructures
Advanced biomarker profiling and analyses
Early Trial Hub
First-in-human, Phase I and Phase I/II oncology clinical trials
Access to CLIP²/CIC certified centers
Expertise in rare cancers and complex patient populations
Dedicated investigators and clinical research teams
Trial set-up and operational implementation
Dedicated clinical capacities and resources
The earlyONCO platform of AP-HP provides end-to-end support for innovative oncology therapies, from early clinical strategy and regulatory guidance to trial implementation, patient identification and recruitment, leveraging AP-HP’s clinical expertise, early-phase trial infrastructures and translational capabilities.